Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1901
Atmus Filtration Technologies
ATMU
$3.73B
| $7.46M | ﹤0.01% |
143,719
+24,675
| +21% | +$1.19M |
2023 Q3
9 quarters
|
|
1902
State Street SPDR EURO STOXX 50 ETF
FEZ
$4.24B
| $7.45M | ﹤0.01% |
115,624
+57,899
| +100% | +$3.65M |
2013 Q2
50 quarters
|
|
1903
BigBear.ai
BBAI
$1.27B
| $7.44M | ﹤0.01% |
1,378,201
+965,140
| +234% | +$6.3M |
2023 Q2
10 quarters
|
|
1904
StoneX
SNEX
$7.94B
| $7.44M | ﹤0.01% |
175,901
+24,057
| +16% | +$1.01M |
2022 Q1
15 quarters
|
|
1905
Red Rock Resorts
RRR
$2.97B
| $7.43M | ﹤0.01% |
120,007
-33,668
| -22% | -$1.97M |
2016 Q3
37 quarters
|
|
1906
BrightSpring Health Services
BTSG
$11.9B
| $7.43M | ﹤0.01% |
198,486
-222,978
| -53% | -$7.48M |
2024 Q1
7 quarters
|
|
1907
Macy's
M
$5.94B
| $7.42M | ﹤0.01% |
336,699
-1,544,080
| -82% | -$31.6M |
2013 Q2
50 quarters
|
|
1908
Bio-Rad Laboratories Class A
BIO
$9.87B
| $7.42M | ﹤0.01% |
24,494
-8,172
| -25% | -$2.55M |
2013 Q2
50 quarters
|
|
1909
SLM Corp
SLM
$4.28B
| $7.41M | ﹤0.01% |
273,964
-120,733
| -31% | -$3.31M |
2013 Q2
50 quarters
|
|
1910
Turning Point Brands
TPB
$1.12B
| $7.41M | ﹤0.01% |
68,357
+41,993
| +159% | +$4.11M |
2019 Q1
27 quarters
|
|
1911
MYR Group
MYRG
$4.75B
| $7.41M | ﹤0.01% |
33,912
+6,794
| +25% | +$1.48M |
2016 Q1
39 quarters
|
|
1912
Novavax
NVAX
$1.73B
| $7.41M | ﹤0.01% |
1,102,300
+574,263
| +109% | +$4.33M |
2013 Q2
50 quarters
|
|
1913
PUT
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$4.1B
| $7.4M | ﹤0.01% |
58,600
| – | – |
2024 Q3
5 quarters
|
|
1914
OneMain Financial
OMF
$6.44B
| $7.38M | ﹤0.01% |
109,324
-45,123
| -29% | -$2.74M |
2013 Q4
48 quarters
|
|
1915
Penske Automotive Group
PAG
$13.4B
| $7.38M | ﹤0.01% |
46,614
+1,599
| +4% | +$263K |
2013 Q2
50 quarters
|
|
1916
Vanguard Morningstar Total Stock Market ETF
VTI
$690B
| $7.37M | ﹤0.01% |
21,995
-20,987
| -49% | -$6.98M |
2017 Q2
34 quarters
|
|
|
CNR
1917
Core Natural Resources Inc
CNR
$4.42B
| $7.36M | ﹤0.01% |
83,107
+992
| +1% | +$84.6K |
2017 Q4
32 quarters
|
|
|
UCB
1918
United Community Banks
UCB
$4.11B
| $7.32M | ﹤0.01% |
234,389
+43,321
| +23% | +$1.34M |
2013 Q2
50 quarters
|
|
1919
Mohawk Industries
MHK
$8.56B
| $7.32M | ﹤0.01% |
66,944
-81,932
| -55% | -$9.41M |
2013 Q2
50 quarters
|
|
1920
Federal Agricultural Mortgage
AGM
$2.33B
| $7.32M | ﹤0.01% |
41,673
+25,420
| +156% | +$4.27M |
2013 Q2
50 quarters
|
|
1921
Ardagh Metal Packaging
AMBP
$2.65B
| $7.31M | ﹤0.01% |
1,784,035
-50,326
| -3% | -$191K |
2022 Q1
15 quarters
|
|
|
SLNO
1922
DELISTED
Soleno Therapeutics
SLNO
| $7.3M | ﹤0.01% |
157,685
-13,295
| -8% | -$729K |
2023 Q4
8 quarters
|
|
1923
Rexford Industrial Realty
REXR
$8.18B
| $7.3M | ﹤0.01% |
188,518
-1,806,397
| -91% | -$74.5M |
2013 Q3
49 quarters
|
|
1924
Trevi Therapeutics
TRVI
$1.98B
| $7.29M | ﹤0.01% |
582,653
+365,768
| +169% | +$4.23M |
2023 Q2
10 quarters
|
|
1925
Pitney Bowes
PBI
$2.3B
| $7.29M | ﹤0.01% |
690,094
+75,813
| +12% | +$786K |
2013 Q2
50 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.